Novocure received Japan approval. Novocure stock fell 4.51 percent

Published on 10/08/2026 at 17:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 183.58 million, 15.60 percent above a year earlier. Novocure stock costs EUR 12.50 on October 8, 2026 versus EUR 13.09.

Key points in brief

Novocure received Japanese approval for Optune Pax to treat locally advanced pancreatic cancer on October 1, 2026.
Second-quarter revenue reached USD 183.58 million, up 15.60 percent year over year, while the adjusted loss per share was USD 0.13.
Novocure stock was trading at EUR 12.50 at Lang & Schwarz on October 8, 2026, down 4.51 percent versus EUR 13.09.

NVCR, JE00BYSS4X48, Illustration mit AI erstellt.

Novocure received Japanese approval for its Optune Pax device on October 1, 2026, while Novocure stock was trading at EUR 12.50 at Lang & Schwarz on October 8, 2026, down 4.51 percent versus the prior close of EUR 13.09. The approval covers adults with unresectable locally advanced pancreatic cancer, adding a regulatory milestone as the company approaches its next quarterly report.

Japan approval expands the commercial case

According to Novocure on October 1, 2026, Japan approved Optune Pax for use alongside standard chemotherapy in the specified pancreatic cancer population. The investor-relations page also lists October 29, 2026 for third-quarter results, giving investors a defined checkpoint for early commercial progress after the approval.

The regulatory decision follows a second quarter in which revenue reached USD 183.58 million, 15.60 percent above the comparable period a year earlier. MarketBeat reported on October 2, 2026 that the company posted a loss per share of USD 0.13 against a consensus loss of USD 0.33, while revenue exceeded the USD 172.44 million consensus estimate.

What does the approval mean for growth?

The comparison is important because revenue growth is moving faster than profitability. NovoCure's second-quarter operating loss was USD 10.56 million and its net loss was USD 15.66 million, while cash and cash equivalents stood at USD 93.70 million at June 30, 2026.

At the primary Nasdaq listing, the finance quote showed USD 14.01 at 11:01 a.m. EDT on October 8, 2026, versus a USD 9.82 to USD 21.45 52-week range. The Lang & Schwarz move is therefore a separate euro-market indication, while the underlying investor debate remains tied to Japanese uptake, reimbursement and the path from revenue growth to sustained profitability.

Results date sets the next test

Novocure's next scheduled reporting date is October 29, 2026, when management is due to discuss third-quarter results before the U.S. market opens. The date matters because the second-quarter revenue comparison and the USD 0.13 loss per share still describe the period ended June 30, 2026, rather than post-approval operating performance.

Novocure had also listed two upcoming investor events on September 2, 2026, before the October 1 approval. The chronology shows a company moving from investor outreach to a concrete regulatory expansion, but the October 8 euro quote reflects a daily decline rather than a confirmed market response to the approval.

Euro quote turns lower

Novocure was trading at EUR 12.50 at Lang & Schwarz on October 8, 2026 at 4:59 p.m. CEST, down 4.51 percent versus the Lang & Schwarz prior close of EUR 13.09. Its market capitalization was USD 1.6 billion on October 8, 2026.

The further course of trading is shown by the continuously updated real-time quote of Novocure stock.